# 1 **A functional variant of the** *SIDT2* **gene involved in cholesterol transport is** 2 **associated with HDL-C levels and premature coronary artery disease.**

3

4 Paola León-Mimila,<sup>1,19</sup> Hugo Villamil-Ramírez,<sup>1,19</sup> Luis R. Macias-Kauffer,<sup>1,19</sup> Leonor Jacobo-5 Albavera,<sup>2,19</sup> Blanca E. López-Contreras,<sup>1</sup> Rosalinda Posadas-Sánchez,<sup>3</sup> Carlos Posadas-6 Romero,<sup>3</sup> Sandra Romero-Hidalgo,<sup>4</sup> Sofía Morán-Ramos,<sup>1,5</sup> Mayra Domínguez-Pérez,<sup>2</sup> Marisol 7 Olivares-Arevalo,<sup>1</sup> Priscilla Lopez-Montoya,<sup>1</sup> Roberto Nieto-Guerra,<sup>1</sup> Víctor Acuña-Alonzo,<sup>6</sup> 8 Gastón Macín-Pérez,<sup>6</sup> Rodrigo Barquera-Lozano,<sup>6</sup> Blanca E. del Río-Navarro,<sup>7</sup> Israel González-9 González,<sup>8</sup> Francisco Campos-Pérez,<sup>8</sup> Francisco Gómez-Pérez,<sup>9</sup> Victor J. Valdés,<sup>10</sup> Alicia 10 Sampieri,<sup>10</sup> Juan G. Reyes-García,<sup>11</sup> Miriam del C. Carrasco-Portugal,<sup>12</sup> Francisco J. Flores-11 Murrieta,<sup>11,12</sup> Carlos A. Aguilar-Salinas,<sup>9,13</sup> Gilberto Vargas-Alarcón,<sup>14</sup> Diana Shih,<sup>15</sup> Peter J. 12 Meikle, <sup>16</sup> Anna C. Calkin, <sup>17, 18</sup> Brian G. Drew, <sup>17, 18</sup> Luis Vaca, <sup>10</sup> Aldons J. Lusis, <sup>15</sup> Adriana Huertas-13 Vazquez,<sup>15</sup> Teresa Villarreal-Molina,<sup>2\*</sup> and Samuel Canizales-Quinteros,<sup>1\*</sup> 14 15 1Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, UNAM/Instituto Nacional 16 de Medicina Genómica (INMEGEN), Mexico City, 14610, Mexico 17 <sup>2</sup> Laboratorio de Enfermedades Cardiovasculares, INMEGEN, Mexico City, 14610, Mexico 18 3Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, 14080, 19 México 20 4Departamento de Genómica Computacional, INMEGEN, Mexico City, 14610, Mexico

21 5Consejo Nacional de Ciencia y Tecnología (CONACyT), Mexico City, 03940, México

22 6Escuela Nacional de Antropología e Historia, Mexico City, 14030, Mexico

23 <sup>7</sup> Hospital Infantil de México Federico Gómez, Mexico City, 06720, Mexico

24 8Hospital General Rubén Leñero, Mexico City, 11340, Mexico

25 9Unidad de Investigación en Enfermedades Metabólicas and Departamento de Endocrinología y

26 Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14000,

27 Mexico

- 28 <sup>10</sup> Instituto de Fisiología Celular, UNAM, Mexico City, 04510, Mexico
- 29 11Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico
- Nacional, Mexico City, 11340, México
- 12Unidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael
- Cosío Villegas, Mexico City, 14080, Mexico
- 13Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud. Monterrey, N.L. 64710, Mexico
- 14Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City,
- 14080, Mexico
- 36 <sup>15</sup> Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of
- California, Los Angeles, CA, 90095, USA
- 38 <sup>16</sup>Head Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC 3004, Australia
- 17Baker Heart and Diabetes Institute, Melbourne, VIC, 3004, Australia
- 18Central Clinical School, Monash University, Melbourne, VIC, 3004, Australia.
- 41 <sup>19</sup>These authors contributed equally to this work.
- 
- \*Correspondence: mvillareal@inmegen.gob.mx (T.V.-M.), cani@unam.mx (S.C.-Q.).
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 

#### **ABSTRACT**

 Low HDL-C is the most frequent dyslipidemia in Mexicans, but few studies have examined the underlying genetic basis. Moreover, few lipid-associated variants have been tested for coronary artery disease (CAD) in Hispanic populations. Here, we performed a GWAS for HDL-C levels in 2,183 Mexican individuals, identifying 7 *loci,* including three with genome- wide significance and containing the candidate genes *CETP*, *ABCA1* and *SIDT2*. The *SIDT2* missense Val636Ile variant was associated with HDL-C levels for the first time, and this 62 association was replicated in 3 independent cohorts  $(P=5.5x10^{-21})$  in the conjoint analysis). The *SIDT2*/Val636Ile variant is more frequent in Native American and derived populations than in other ethnic groups. This variant was also associated with increased ApoA1 and glycerophospholipid serum levels, decreased LDL-C and ApoB levels and a lower risk of premature CAD. Because SIDT2 was previously identified as a protein involved in sterol transport, we tested whether the SIDT2/Ile636 protein affected this function using an *in vitro* site- directed mutagenesis approach. The SIDT2/Ile636 protein showed increased uptake of the cholesterol analog dehydroergosterol, suggesting this variant is functional. Finally, liver transcriptome data from humans and the Hybrid Mouse Diversity Panel (HMDP) are consistent with the involvement of *SIDT2* in lipid and lipoprotein metabolism. In conclusion, this is the first study assessing genetic variants contributing to HDL-C levels and coronary artery disease in the Mexican population. Our findings provide new insight into the genetic architecture of HDL-C and highlight *SIDT2* as a new player in cholesterol and lipoprotein metabolism in humans.

#### 77 **INTRODUCTION**

78

79 Observational epidemiologic studies have reported that low plasma high density 80 lipoprotein cholesterol (HDL-C) concentrations are an independent risk factor for cardiovascular 81 disease.<sup>1-4</sup> Heritability of HDL-C serum levels has been estimated as high as 70% in various 82 populations, including Mexican-Americans.<sup>5-8</sup> Genome wide association studies (GWAS) have 83 successfully identified more than 150 loci associated with lipid levels mainly in European 84 populations,<sup>9-12</sup> while relatively few GWAS have been performed in Mexicans.<sup>13-16</sup> The main 85 HDL-C associated loci identified in Europeans are also associated with HDL-C levels in 86 Mexicans, although novel loci have been reported in the latter group.<sup>14</sup> Notably, a functional 87 variant apparently private to the Americas (*ABCA1* Arg230Cys) was found to be associated with 88 Iower HDL-C levels in Mexicans.<sup>17; 18</sup> Although low HDL-C levels are a well-established 89 cardiovascular risk factor, Mendelian randomization studies have shown that most genetic 90 variants associated with this trait are not associated with cardiovascular risk, suggesting that this 91 relationship is not necessarily causal.<sup>19-21</sup> In this regard, it has been postulated that pleiotropic 92 effects of the genetic variants or HDL-C particle functionality rather than HDL-C plasma 93 concentrations may affect cardiovascular risk.<sup>22-25</sup>

94

95 Low HDL-C levels are highly prevalent in the Mexican population.<sup>26-28</sup> This population group has been underrepresented in GWAS, and few lipid-associated variants have been tested 97 for coronary artery disease (CAD) risk in Mexicans.<sup>29</sup> Therefore, we performed a GWAS for HDL-C levels in a cohort of Mexican individuals, using a multiethnic array that includes rare and common genetic variants for Hispanic populations. We then sought to replicate these associations in two independent cohorts: the Genetics of Atherosclerotic Disease (GEA) and the Morbid Obesity Surgery (MOBES) studies, and to test their possible effect on CAD risk. Lastly,



 weight and 527 with obesity. The Mexican adult cohort includes 1,073 adults aged 18-82 years, 486 with normal-weight and 587 with obesity. Recruitment strategies, inclusion criteria, anthropometric and biochemical characteristics of both ORSMEC and the Mexican Adult cohorts 117 have been previously described.<sup>31; 32</sup> Demographic and biochemical characteristics are described in Tables S1 and S2. Briefly, obesity, height and weight were measured following 119 standard protocols and calibrated instruments as previously described.<sup>31</sup> BMI was calculated as 120 body weight in kilograms divided by the square of height in meters ( $\text{kg/m}^2$ ). In adults, obesity 121 was defined as a BMI ≥30 kg/m<sup>2</sup> and normal weight as BMI <25 kg/m<sup>2</sup> and ≥18.5 kg/m<sup>2</sup> 122 according to World Health Organization (WHO) criteria.<sup>33</sup> In children, BMI percentile was calculated using age and sex specific BMI reference data, as recommended by the Centers for Disease Control and Prevention, and obesity was defined as BMI percentile ≥95 and normal 125 weight as BMI percentile > 25 and ≤75.<sup>34</sup>

*Replication phase cohorts*

#### *Genetics of Atherosclerotic Disease (GEA) cohort*

 The GEA study was designed to examine the genetic bases of premature CAD in the Mexican population. We included 1,095 adults with premature coronary artery disease and 1,559 individuals recruited as controls without CAD or family history of premature CAD, 413 of which had subclinical atherosclerosis defined by the presence of coronary artery calcification on helical computed axial tomography. Recruitment strategy, inclusion criteria, anthropometric and 134 biochemical characteristics have been previously described.<sup>29</sup> Demographic and biochemical characteristics are described in Table S3.

#### *The Mexican Obesity Surgery (MOBES) cohort*

 This cohort was designed to study the genetic and metabolomic bases of obesity and 139 metabolic traits in Mexicans and includes 555 individuals with obesity (BMI ≥35kg/m<sup>2</sup>) aged 18 to 59 years who underwent bariatric surgery at the Rubén Leñero General Hospital in Mexico 141 City. Inclusion criteria of this cohort were previously described.<sup>35</sup> Demographic and biochemical characteristics of this cohort are described in Table S4.

#### *Native Americans*

 This cohort included 302 unrelated Native American individuals (Totonacs and Nahuas from East-central Mexico) aged over 18 years. Inclusion criteria, anthropometric and biochemical 147 characteristics of these individuals have been previously described.<sup>18</sup> Demographic and biochemical characteristics of these individuals are described in Table S5.

*Ethics Statement*

 This study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the Ethics Committees of participant institutions. All adult participants provided written informed consent prior to inclusion in the study. For children,

 parents or guardians of each child signed the informed consent and children assented to participate. For Totonac and Nahua participants a translator was used as needed.

#### *Biochemical measurements*

 For all cohorts, blood samples were drawn after 8-12 hours of overnight fasting to determine the serum levels of total cholesterol (TC), triglycerides (TG) and high-density 160 lipoprotein cholesterol (HDL-C) by enzymatic assays as previously described.<sup>31</sup> Low density 161 lipoprotein-cholesterol (LDL-C) levels were calculated with the equation of Friedewald *et al.*<sup>36</sup> In the GEA cohort, LDL-C levels were estimated with the equation of Friedewald modified by 163 DeLong *et al.*,<sup>37</sup> and serum levels of Apolipoprotein A1 and B (ApoA1 and ApoB) were measured by immunonephelometry in a BN Pro Spec nephelometer (Dade Behring Marburg GmBH). In children, low HDL-C levels were defined as HDL-C <40 mg/dL according to the US National Cholesterol Education Program (NCEP) Expert Panel on Cholesterol Levels in Children and Adolescents. For adults low HDL-C levels were defined as HDL-C ≤40 mg/dL for men and ≤50 168 mg/dL for women according to the US NCEP Adult Treatment Panel III (ATP III).<sup>38</sup>

#### *Lipidomic study in the MOBES cohort*

 Lipidomic analysis was performed using 375 serum samples from MOBES cohort 172 participants with previously described methods.<sup>39; 40</sup> Briefly, liquid chromatography–electrospray ionization–tandem mass spectrometry (LC–ESI–MS/MS) was used for lipidomic analysis on an Agilent 1290 liquid chromatography system. Liquid chromatography was performed on a Zorbax Eclipse Plus 1.8 µm C18, 50 × 2.1 mm column (Agilent Technologies). The mass spectrometer was operated in dynamic/scheduled multiple reaction monitoring (dMRM) mode. There were 630 unique lipid species belonging to 31 lipid classes identified together with 15 stable isotope or non-physiological lipid standards.

#### *GWAS and quality control*

 Genomic DNA was isolated from peripheral white blood cells using standard methods. A total of 2,153 children and adults included in the discovery phase were genotyped using the Multi-Ethnic Genotyping Array (MEGA, Illumina, San Diego, CA, USA), which included >1600k SNPs. This array includes both common and rare variants in Latin American, African, European 185 and Asian populations. Standard quality control (QC) measures were as previously described.<sup>32</sup> 186 Identity-by-descent (IBD) was estimated using Plink v1.07.<sup>41</sup> A total of 624,242 SNPs remained 187 after QC measures. After imputation with Beagle,<sup>42</sup> 865,896 SNPs were included in the final analysis. The quantile-quantile (QQ) plot for the HDL-C GWAS was well calibrated for the null hypothesis (λGC = 1.017), indicating adequate control for confounders (Figure S1).

#### *Selection of SNPs for the replication analyses*

 Ten SNPs at 7 loci found to be significantly associated with HDL-C levels in the 193 discovery phase (*P*<1×10<sup>-6</sup>) were selected for replication in two independent cohorts (GEA controls and MOBES). These were the lead SNP of 4 loci (rs9457930 in *LPAL2*, rs983309 in *PPP1R3B*, rs1514661 in *ADAMTS20* and rs1077834 in *LIPC*), and 6 independent SNPs at 3 loci (rs12448528 and rs11508026 in *CETP*, rs9282541 and rs4149310 in *ABCA1*, and rs17120425 and rs10488698 near the *APOA5* cluster). SNPs were defined as independent when LD with 198 other variants within the locus was low ( $r^2$  and D' <0.2). Selected SNPs were genotyped using KASP assays (LGC, U.S. http://www.lgcgroup.com). The *SIDT2/* rs17120425 variant was also genotyped in 302 Native Mexicans using a TaqMan assay (ABI Prism 7900HT Sequence Detection System, Applied Biosystems). Call rates exceeded 95% and no discordant genotypes were found in 10% of duplicate samples. No SNPs deviated from Hardy–Weinberg equilibrium in any group (*P*>0.05).

#### *Mendelian Randomization*

206 In order to test the causal effect of HDL-C levels on CAD we performed Mendelian 207 Randomization (MR) analyses by using HDL-C associated SNPs as an instrument. In MR 208 analyses, genetic variants act as proxies for HDL-C levels in a manner independent of 209 confounders.<sup>43</sup> We used the inverse-variance weighted (IVW) method<sup>44</sup> which assumes that all 210 genetic variants satisfy the instrumental variable assumptions (including zero pleiotropy). We 211 also performed MR-Egger regression, $45$  which allow each variant to exhibit pleiotropy. Only 212 SNPs found to be associated with HDL-C in the GEA cohort (n=7) were included in the MR 213 analyses. Both methods were performed with the aid of the Mendelian Randomization R 214 package.<sup>46</sup>

215

#### 216 *Ancestry Analysis*

217 Global ancestry was estimated as previously described.<sup>32</sup> Briefly, European (CEU) and 218 Yoruba (YRI) individuals from the 1000 genomes project and fifteen Nahua and Totonac trios 219 (Native American or NAT) were used as reference populations for ancestry analyses. 220 Multidimensional scaling components were calculated in Plink v1.07.<sup>41</sup> Ancestral proportions 221 were determined with Admixture.<sup>47</sup> Local ancestry was determined to identify the origin of 222  $\phantom{1}$  chromosomal segments within the 11q23 region using RFMix. $^{48}$ 

223

#### 224 *Positive selection analysis of* **the** *SIDT2 Val636Ile variant*

 Extended haplotype homozygosity (EHH) values were estimated to seek whether the *SIDT2* derived "A" allele shows evidence of positive selection in a sample of Native Mexican 227 individuals. Sabeti *et al.<sup>49</sup>* introduced EHH to exploit the decay of haplotype homozygosity as a function of genetic distance from a focal SNP. For this purpose, we used SNP 6.0 microarray data (Affymetrix) from 233 Native Mexicans (Nahuas and Totonacs), and genotyped 230 SIDT2/rs17120425 in these individuals. The merged data were phased using Beagle.<sup>42</sup> Phased

 alleles were coded as 0/1 (ancestral "G"/derived "A") to obtain EHH values using the Selscan 232 program.<sup>50</sup>

#### *HEK293T cell cultures and wildtype and SIDT2/Ile636 transfection*

 Human embryonic kidney (HEK293T) cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cells were grown on 35 mm culture dishes using Dulbecco's modified Eagles medium (DMEM) (Invitrogen, Carlsbad, CA) supplemented with 10% of heat inactivated fetal bovine serum (Wisent, premium quality, Canada), penicillin- streptomycin and glutamine (Life Technologies) in an incubator with humidity control at 37 °C 240 and  $5\%$  CO<sub>2</sub>.

 Human *SIDT2* was cloned from human cDNA CGI-40 (AF151999.1) obtained from the Riken Consortium (Japan). The product was cloned in pEGFP-N1 (Clontech, Mountain View, CA. USA). The SIDT2/Ile636 variant was produced using the QuikChange® Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, CA. USA) following manufacturer's instructions. The wildtype SIDT2/Val636 variant will be referred to as SIDT2, and the isoleucine variant will be referred as Ile636/SIDT2. The primers used to change valine for isoleucine were the following: FORWARD 5´- GCGTTCTGGATCATTTTCTCCATCATT-3´ and REVERSE 5´- CGCAAGACCTAGTAAAAGAGGTAGTAA-3´. Constructs were sequenced prior to use.

 The plasmids containing SIDT2-GFP and Ile636/SIDT2-GFP were transfected to HEK293T cells grown on 35 mm Petri dishes with a glass bottom (MatTek, Ashland, MA, USA). 253 For transfection we used a mixture of 1 µg of DNA and 6 µ CaCl<sub>2</sub> reaching 60 µ of final volume 254 with distilled H<sub>2</sub>O. The mixture was added by dropping to HeBS buffer (50mM HEPES, 280mM 255 NaCl, 1.5mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.05) and the final mixture was incubated for 30 minutes prior to

 replacing with DMEM. The cells were incubated overnight with the transfection mixture, which was then replaced with fresh medium to perform the assays 24 hours later.

#### *Fluorescent cholesterol analog dehydroergosterol (DHE) uptake experiments*

 The naturally occurring blue fluorescent cholesterol analog DHE was purchased from Sigma (Saint Louis, MO). HEK293T cells expressing either SIDT2-GFP or SIDT2/Ile636-GFP were incubated with 5mM DHE solution, adding 300 mM methyl-β-cyclodextrin (MβCD). The solution was carefully resuspended and diluted in PBS to obtain a DHE/MβCD ratio of 1:8 (mol/mol) and 100 µL of this solution were added to the HEK293T cells. Cells were monitored using the scanning confocal microscope (FV1000, Olympus Japan). Focal plane was positioned at the middle of the cells. Confocal images were acquired every 15 seconds with no averaging to reduce photobleaching. Excitation was at 300 nm using a solid-state laser and emission was collected at 535 nm.

#### *Liver transcriptome analysis in the Hybrid Mouse Diversity Panel (HMDP) and humans*

 *HMDP*: The HMDP is a collection of approximately 100 well-characterized inbred strains 272 of mice that can be used to analyze the genetic and environmental factors underlying complex traits such as dyslipidemia, obesity, diabetes, atherosclerosis and fatty liver disease. We analyzed the liver transcriptome of strains from this panel carrying the human cholesteryl ester transfer protein (CETP) and the human ApoE3-Leiden transgenes. At the age of about 8 weeks, these mice were placed on a "Western Style" synthetic high fat diet supplemented with 1% 277 cholesterol.<sup>51</sup> After 16 weeks on this diet, plasma lipid profiles were measured by colorimetric 278 analysis as previously described<sup>52; 53</sup> and animals were euthanized for the collection of liver tissue. Total RNA was isolated from the left lobe using the Qiagen (Valencia, CA) RNeasy kit 280 (cat# 74104), as described.<sup>54</sup> Genome wide expression profiles were determined by hybridization to Affymetrix HT-MG\_430 PM microarrays. Microarray data were filtered as

282 previously described.<sup>55</sup> The ComBat method from the SVA Bioconductor package was used to 283 remove known batch effects.<sup>56</sup> All animal work was conducted according to relevant national and international guidelines and was approved by the UCLA Institutional Animal Care and Use Committee (IACUC).

 *Humans*: Total RNA was extracted from liver biopsies of 144 MOBES participants using Trizol reagent (Invitrogen). Clinical and biochemical characteristics of this subgroup of patients 289 are described in Table S6. RNA sequencing was performed as previously described.<sup>57</sup> Briefly, RNA quality was assessed using the Bioanalyzer RNA chip analysis to ensure that the RNA integrity number was >7. Complementary DNA libraries were prepared using the TruSeq RNA Stranded Total RNA Library Preparation kit (Illumina) and sequenced using an Illumina HiSeq2500 instrument, generating approximately 50 million reads/sample. After data quality control, sequencing reads were mapped to the human reference genome using TopHat software  $\,$  v2.0.1 $^{58}$  and quantified using Cufflinks software. $^{59}$ 

#### *Statistical Methods*

 For the discovery phase, genome-wide association with HDL-C was tested independently in 4 groups (normal-weight and obese children and normal-weight and obese adults) under an additive linear mixed model with sex, age and BMI percentile (children) or BMI (adults) as fixed effects, and the genetic relatedness matrix as a random effect. An inverse variance method was 302 used to perform a meta-analysis of the 4 groups.<sup>60</sup> Genetic relationship matrices from genome-303 buide data were considered for the analysis using GCTA software.<sup>61</sup> A P-value <1×10<sup>-8</sup> was Considered genome-wide significant, suggestive significance was defined as a *P*-value <1×10<sup>-6</sup>. 305 Group heterogeneity in the meta-analysis was evaluated by  $I^2$  and Cochrane's  $Q^{62}$  using the R package meta. We used publicly available databases such as the GWAS Catalog

 (https://www.ebi.ac.uk/gwas/home) to annotate associated SNPs. SNPs within a 1Mb range of 308 the SIDT2/Val636Ile variant were included in a locus zoom plot.<sup>63</sup>

 For the validation phase, linear regression under additive models was used to test for genetic associations with lipid traits (HDL-C, LDL-C, TC and TG levels) in the GEA control, MOBES and Native American cohorts, and to test for associations with lipid classes in the MOBES cohort. Genetic associations with premature CAD in the GEA cohort were tested using multiple logistic regression under additive models. All tests were adjusted by age, sex and BMI. Associations were tested using the SPSS Statistics package (IBM SPSS Statistics, version 24, Chicago, IL, USA), and statistical significance was considered at *P*<0.05.

 Correlations of *SIDT2* liver expression with serum lipid levels and the liver transcriptome were performed using biweight midcorrelation (bicor) coefficient with the R package WGCNA, a 320 robust alternative to Pearson's correlation coefficient not sensitive to outliers. Genes 321 significantly correlated with *SIDT2* expression in liver ( $P≤1.0x10<sup>-4</sup>$ ) were tested for pathway 322 enrichment analysis using Metascape and ToppGene Suite software.<sup>65; 66</sup> Enrichment *P* values 323  $\leq$  0.05 after FDR correction were considered significant.<sup>67</sup>

#### **RESULTS**

 Low HDL-C levels were highly prevalent in Mexican children and adults (38 and 27%, respectively). This trait was significantly more frequent in obese as compared to lean individuals (43.6% vs 12.7% respectively in children, and 81.6% vs 35.4% respectively in adults; *P*<0.001) (Tables S1 and S2). To identify loci associated with HDL-C levels, we carried out a GWAS in 2 independent cohorts of Mexican children and adults using a multi-ethnic array. Of note, the

 same HDL-C associated loci were found in children and adults, regardless of obesity status, and effect sizes were similar and showed the same directionality. There was no significant evidence of heterogeneity (Table S7), and therefore a fixed-effects meta-analysis was conducted.

 In total, we identified 64 variants distributed across 7 *loci* associated with HDL-C levels 338 with genome wide or suggestive significance ( $P$ <1.0x10<sup>-6</sup>) after adjusting for age, sex, BMI and ancestry (Figure 1, Table S7). Most of the 64 variants were also associated with other lipid 340 parameters (Table S7). Four SNPs showed genome-wide significance (P<1.0x10<sup>-8</sup>), rs11508026 and rs12448528 within the *CETP* locus on chromosome 16 (B=3.02 mg/dL; 342 *P*=4.46x10<sup>-18</sup> and B=-2.79 mg/dL; *P*=5.92x10<sup>-15</sup>, respectively); rs9282541 within the *ABCA1* 343 gene on chromosome 9 (Arg230Cys, B=-3.44 mg/dL;  $P=3.99x10^{-13}$ ); and rs17120425 within the 344 SIDT2 gene (Val636Ile, B=3.31 mg/dL;  $P=1.52\times10^{-11}$ ), the latter associated with HDL-C levels for the first time (Table 1). The gender stratified meta-analysis showed that the effect size of 346 SIDT2/Val636Ile on HDL-C levels was similar in females (B=3.48, P=1.9x10<sup>-7</sup>) and males 347 (B=3.27, P=1.4x10<sup>-5</sup>) (Table S8). Figure 2 shows the locus zoom plot for the rs17120425 (*SIDT2)* region, including 658 SNPs spanning 1 Mb in chromosome 11q23. No nearby SNPs in 349 LD ( $r^2$ >0.2) with rs17120425 (*SIDT2*) were found.

 Notably, minor allele frequencies of *ABCA1*/Arg230Cys and *SIDT2*/Val636Ile variants are highest in populations from the Americas (Table S9). We then genotyped the *SIDT2/*Val636Ile variant in two independent Native American populations from central Mexico (Totonacs and Nahuas), which was also associated with higher HDL-C levels in these indigenous groups (B=2.81 mg/dL; *P*=0.027) (Table S10). Moreover, the rs17120425 "A" allele was significantly more frequent in Native Mexicans (15%) than in Mexican Mestizos (10.3%, *P*=0.001) (Table S9), and local ancestry analysis revealed that this allele was found in a block of Native American origin in 98% of individuals. However, according to EHH analysis, LD

 extension break down was similar in the ancestral and derived rs17120425 alleles, with no evidence of positive selection (Figure S2).

#### *Replication of associations with HDL-C Levels and other lipid traits in independent*

*cohorts*

 We then sought to replicate associations with HDL-C levels in 1,559 controls without CAD from the GEA cohort. Seven of the 10 variants associated with HDL-C levels in the discovery phase replicated in GEA controls (*P<*0.010, Table 2): rs12448528 and rs11508026 367 within the *CETP* gene (*P*=7.2x10<sup>-11</sup> and *P*=2.9x10<sup>-9</sup>, respectively), rs983309 (*PPP1R3B*, *P*=4.0x10<sup>-6</sup>), rs17120425/Val636Ile (*SIDT2, P*=7.0x10<sup>-6</sup>), rs9282541 and rs4149310 (*ABCA1, P*=2.0x10-5 369 and *P=*0.01, respectively) and rs10488698 (*BUD13-ZPR1-APOC3-APOA4-APOA5- APOA1* cluster, *P*=6.5x10-5 ). Altogether, these seven variants explained ~25% of HDL-C level 371 variation ( $P_{\text{Genetic Risk Score}}$ =7.0x10<sup>-15</sup>). Table 2 shows associations of these SNPs with other lipid traits in the GEA cohort. *SIDT2/*/Val636Ile and rs10488698 (*BUD13-ZPR1-APOC3-APOA4- APOA5-APOA1* cluster) were both associated with higher HDL-C and ApoA1 levels and lower LDL-C and ApoB levels. SNP rs10488698, but not *SIDT2*/Val636Ile was also significantly associated with lower TG levels. These two SNPs were the only variants associated both with higher ApoA1 and lower ApoB levels. In the MOBES cohort which includes 555 individuals with obesity, rs11508026 (*CETP*, *P=*9.6x10-5), rs9282541 (*ABCA1, P*=1.1x10-4 ) and *SIDT2/*Val636Ile (*P=*0.003) were significantly associated with HDL-C levels (Table 3).

 The association of *SIDT2*/Val636Ile with HDL-C levels was highly significant in the 381 conjoint analysis including the discovery phase and replication cohorts ( $B=3.21$ ,  $P=5.5x10^{-21}$ ).

 *The SIDT2 Val636Ile variant is associated with serum glycerophospholipid levels in the MOBES cohort.*

 We then sought associations of the 4 HDL-C associated SNPs in the MOBES cohort with lipid classes known to be the main components of HDL-C lipoprotein particles (19 classes of cholesterol esters, phospholipids and TG). 68; 69 *SIDT2/Val636Ile* was significantly associated with higher glycerophospholipid serum levels (*P*<0.05) (Figure 3), particularly with total phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI) and phosphatidylserine (PS) as adjusted by age, sex, BMI and lipid lowering treatment. In contrast, *ABCA1* (rs9282541) and *CETP* variants (rs12448528 and rs11508026) were not significantly associated with any of these lipid classes.

#### *Association with premature CAD and Mendelian randomization*

 We then tested whether HDL-C variants were also associated with premature CAD in the GEA cohort. Four of the ten variants were significantly associated with CAD risk (rs9282541/*ABCA1*, rs10488698/*APOA1* cluster, rs1077834/*LIPC* and rs17120425/*SIDT2*). Rs10488698/*APOA1-*cluster and *SIDT2/*Val636Ile variants were associated with higher HDL-C levels and lower CAD risk, while rs9282541 (*ABCA1*) and rs1077834 (*LIPC*) were associated with both lower HDL-C levels and lower CAD risk (Table 4). Mendelian randomization analyses were performed including only the 7 variants significantly associated with HDL-C levels in the GEA control cohort. There was no evidence of a causal effect of HDL-C levels on CAD (IVW *P*=0.253 and MR-Egger *P*= 0.509) (Table S11).

#### **Fluorescent cholesterol analog uptake is enhanced in cells expressing Ile636/SIDT2.**

 It was previously suggested that the transmembrane conserved cholesterol binding (CRAC) domain of murine Sidt2 associates with the cholesterol analogue dehydroergosterol in HEK293 cells. <sup>30</sup> Because the *SIDT2*/Val636Ile variant is near the transmembrane CRAC domain in the human SIDT2 protein, we evaluated the effect of this variant on DHE uptake in HEK293T cells. Interestingly, DHE uptake was enhanced in cells expressing the Ile636/SIDT2 protein as

 compared to cells expressing wildtype SIDT2, reaching the highest difference approximately 1.5 minutes after adding DHE to the culture (6.85 ± 0.42 AU vs 9.40 ± 0.73 AU, *P*<0.01) (Figure 4, Video S1).

# *SIDT2 liver expression correlates with the expression of genes involved in lipid and lipoprotein metabolism*

 In the MOBES cohort, hepatic *SIDT2* expression did not differ according to the presence of the Val636Ile variant (*P=*0.486). Moreover, human *SIDT2* liver expression showed no significant correlation with lipid traits including HDL-C, TC, or TG levels (Figure 5A). In contrast, in HMDP mice fed with an atherogenic diet, hepatic *Sidt2* expression correlated positively with HDL-C levels (r=0.312, *P*=0.002), and negatively with total cholesterol and TG levels (r=-0.381, *P*=1.2x10<sup>-4</sup>; r=-0.304, *P*=0.002, respectively) (Figure 5B).

 To analyze correlations between *SIDT2* expression and the liver transcriptome in mice, we used data from the genetically diverse HMDP where environmental factors are controlled. A total of 2,240 genes showed significant correlations with *Sidt2* expression, and the most 427 significantly enriched pathway was lipid and lipoprotein metabolism ( $P_{FDR}$ =1.5x10<sup>-7</sup>). In human liver tissue *SIDT2* expression correlated with the expression of 2,782 genes. Consistent with observations in mice, the lipid and lipoprotein metabolism pathways were among the most significantly enriched. *SIDT2* expression correlated with the expression of 227 genes that were shared by both mice and humans, and as expected metabolism of lipids and lipoproteins was the most significantly enriched pathway (Figure 5C-D).

- 
- 

```
435 DISCUSSION
```
 Low HDL-C levels are the most common dyslipidemia in Mexicans, both in adults and 438 children.<sup>26; 28</sup> Consistently, low HDL-C levels were highly prevalent in children and adults of the present study. Moreover, the prevalence of low HDL-C levels was significantly higher in obese than in lean individuals, in line with the high prevalence of metabolic syndrome observed in the 441 Mexican population.<sup>70</sup>

 Here, using a GWAS for HDL-C levels in different cohorts of the Mexican population, we identified three loci associated with HDL-C levels at chromosomes 9, 11 and 16. Of note, the effect and direction of the associations were consistent in the 4 study groups (normal weight and obese children and adults). The most significant signal corresponds to the *CETP* locus, which is 447 but known to be one of the main drivers of HDL-C levels across populations.<sup>10; 15; 71</sup> The signal in chromosome 9 is the *ABCA1*/Arg230Cys variant (rs9282541) previously reported as associated with lower HDL-C levels by our group, apparently private to Native American and derived  $\;$  populations. $^{17; -18}$  The third genome-wide significant signal corresponds to a missense variant within the *SIDT2* gene (Val636Ile, rs17120425), associated with higher HDL-C levels. This association was replicated in 3 independent cohorts including Native Americans from Mexico. This is relevant because Native Americans live in rural areas, while the GEA and MOBES cohorts are urban populations, known to have different dietary habits, which may affect HDL-C 455 levels. $^{72}$ 

 To our knowledge, this is the first time that the *SIDT2*/Val636Ile variant has been associated with HDL-C levels. However, intronic *SIDT2* variants have been previously associated with lipid traits and the metabolic syndrome in multi-ethnic cohorts, mainly in 460 Koreans.<sup>73; 74</sup> Nevertheless, these variants (rs2269399, rs7107152, rs1242229 and rs1784042) 461 are not in LD with *SIDT2/Val636Ile* (r<sup>2</sup><0.2). Although the *SIDT2/Val636Ile variant is not private* to the Americas, it is more frequent in Native Americans (15%) and Hispanics (6%), than other

 ethnic groups (internationalgenome.org). Local ancestry analyses revealed that the derived "A" allele was of Native American origin in most individuals. However, the extended haplotype homozygosity (EHH) analysis of *SIDT2*/Val636Ile did not show evidence of recent positive selection.

 It is likely that previous GWAS in Mexicans failed to identify this SNP as associated with HDL-C because this variant was not included in the microarray platforms used in these studies 470 and the paucity of Native American references for imputation.<sup>13-16</sup> This 11q23 region contains several lipid-associated signals, and it is thus necessary to define whether these signals are independent of *SIDT2*/Val636Ile. The *BUD13-ZPR1-APOC3-APOA4-APOA5-APOA1* cluster associated with TG levels is 400 Kb upstream *SIDT2*. Our regional LD analysis demonstrated 474 the lead TG-associated SNP rs964184 (*APOA5*)<sup>9; 13</sup> and all other SNPs analyzed within this 475 cluster were in low LD with *SIDT2/Val636Ile (r<sup>2</sup><0.2)*. This indicates that the *SIDT2* signal associated with HDL-C and SNPs within the *BUD13-ZPR1-APOC3-APOA4-APOA5-APOA1*  cluster are in fact independent. Moreover, a previous GWAS in the Mexican population identified two intronic *SIK3* gene variants within the 11q23 region, rs139961185 associated with 479 TG levels and rs11216230 with higher HDL-C levels.<sup>14</sup> The latter association was replicated in 480 an independent Hispanic population.<sup>16</sup> Of note, rs11216230 is more frequent in Mexicans (11%) than in Europeans (1%) and is in high LD with *SIDT2*/Val636Ile in Mexican Americans from the 482 1000 Genomes project (r<sup>2</sup>=0.75). This suggests that the association observed by Ko *et al.*<sup>14</sup> could be driven by the *SIDT2*/Val636Ile variant.

 In Mendelian randomization analyses, genetic variants act as proxies for HDL-C levels in a manner independent of confounders to analyze the causality of HDL-C levels on coronary artery disease. Our MR analysis is consistent with previous studies suggesting that higher HDL- $\phantom{1}$  C levels are not causally protective against coronary heart disease.<sup>19-21</sup> This suggests that the

 effect of individual variants on CAD risk may be mediated by pleiotropic effects on other 490 cardiovascular risk factors, or on HDL-C composition and functionality.<sup>22-25; 75</sup> The *SIDT2*/Val636Ile variant was associated with higher HDL-C levels and with lower risk of premature CAD. We thus explored whether this variant affects other cardiovascular risk parameters in addition to HDL-C levels. Notably, *SIDT2*/Val636Ile was also associated with higher ApoA1 levels, and lower LDL-C and ApoB serum levels in the GEA cohort. APOA1 is the major protein component of HDL-C particles, and a Mendelian randomization analysis in Finnish  $\,$  individuals reported that ApoA1 was not associated with risk of CAD. $^{76}$  A multivariable Mendelian randomization study examining serum lipid and apolipoprotein levels reported that 498 only ApoB retained a robust relationship with the risk of  $CAD$ , $77$  and recent Mendelian randomization studies suggest that ApoB is the primary lipid determinant of cardiovascular 500 disease risk.<sup>78; 79</sup> Thus, the association of *SIDT2/V*al636Ile with decreased cardiovascular risk could be mediated by its effect on ApoB levels.

503 HDL lipidome composition has been associated with HDL-C functional properties, $80-82$  Notably, of the 4 main variants associated with HDL-C levels in the present study, only *SIDT2*/Val636Ile was associated with lipid species, specifically with higher serum concentrations of several glycerophospholipid classes including PE, PG, PC, PI and PS. It has been reported 507 that HDL-C particles enriched in phospholipids can increase HDL-C stability,  $^{83}$  while decreased levels of phospholipids in HDL-C were found to impair cholesterol efflux and decrease the 509 cardiovascular protective effects of HDLs.<sup>69; 82; 84</sup> Particularly, recent studies indicate that phosphatidylserine, a minor component of the monolayer surface of HDL-C, is enriched in small, 511 dense HDL-C particles, which display potent anti-atherosclerotic activities.<sup>83; 85</sup> Although we measured phospholipids in serum and not directly in HDL-C particles, a limitation of the study, the association of *SIDT2*/Val636Ile with higher phospholipid levels is consistent with the lower cardiovascular risk conferred by this variant.

515

516 The SIDT2 protein is found mainly in lysosome membranes,<sup>86</sup> is a lysosomal nucleic acid 517 transporter, and is expressed in several tissues, including the liver.<sup>87-91</sup> The mammalian SIDT2 518 protein has high homology to the *C. elegans* cholesterol uptake protein-1 (CUP-1).<sup>92</sup> SIDT2 has 519 been identified as a sterol-interacting protein<sup>93</sup> and more recently as a cholesterol-binding 520 protein.<sup>30</sup> Moreover, SIDT2 is predicted to contain two CRAC domains (Cholesterol 521 Recognition/interaction Amino Acid Consensus), found in a broad range of proteins involved in 522 cholesterol transport, metabolism and regulation. $^{30;94}$  Specifically, the transmembrane CRAC 523  $\,$  domain from human SIDT1 and mouse SIDT2 appears to bind cholesterol. $^{30}$  The Val636IIe 524 variant and the CRAC domain are located within the same transmembrane segment, and this 525 variant is 19 amino acids upstream the tyrosine CRAC domain residue, suggested to interact 526 with the cholesterol OH-polar group.<sup>30</sup> It is unknown if the Val636Ile variant modifies the 527 interactions of the CRAC domain with cholesterol, thus affecting circulating lipid levels.

528

 In the present study, HEK293T cells expressing the Ile636/SIDT2 protein showed higher cholesterol analog DHE uptake than those expressing the wildtype protein. This increased uptake observed *in vitro*, may affect circulating levels of cholesterol-rich lipoproteins. Although the mechanism by which this variant increases HDL-C serum levels is unknown, ABCA1- mediated cholesterol efflux and HDL-C formation are primarily dependent on autophagy for 534 cholesterol source.<sup>95</sup> Because Sidt2<sup>-/-</sup> deficient mice show blocked autophagosome maturation 535 and altered hepatic lipid homoeostasis, $96$  it is tempting to speculate that the putative increased function of the Ile636 SIDT2 protein may enhance autophagy-mediated cholesterol flux, and thus ABCA1-mediated HDL-C formation.

538

539 *Sidt2* knockout mice show a wide range of metabolic phenotypes including impaired 540 glucose tolerance likely due to compromised NAADP-involved insulin secretion.<sup>96-100</sup> Meng *et* 

541 al.,<sup>100</sup> showed that *Sidt2* deficient mice present significantly increased serum total cholesterol, 542 TG and LDL-C levels, and significantly lower HDL-C serum levels as compared to  $Sid2^{+/+}$  mice. These findings are consistent with the inverse correlation between hepatic *Sidt2* expression and total cholesterol and triglycerides levels, and the direct correlation of *Sidt2* expression with HDL- $\degree$  C levels observed in the HMDP. Moreover, *Sidt2<sup>-1</sup>* mice not only have altered lipid serum levels, 546 but also showed impaired liver function and liver steatosis.<sup>96; 99; 100</sup> Consistently, *Sidt2* expression correlated with increased fat liver content in HMDP mice (data not shown). In contrast, in the MOBES cohort *SIDT2* liver expression did not correlate with serum lipid levels or liver steatosis, and the *SIDT2*/Val636Ile variant showed no association with non-alcoholic fatty liver disease in the GEA or MOBES cohorts (data not shown). Because MOBES cohort participants had morbid obesity and do not represent the overall population, the lack of correlation between *SIDT2* liver expression with lipid levels in this cohort must be interpreted with caution. Despite these differences between mice and humans, *SIDT2* expression correlations with the liver transcriptome revealed that the most significantly enriched pathways were lipid and lipoprotein metabolism in both species. Altogether, these findings support a role of SIDT2 in lipid metabolism. Further studies are required to better understand the mechanisms by which SIDT2 participates in cholesterol and lipoprotein metabolism at the cellular and systemic levels, and its role in cardiovascular risk.

 In conclusion, this is the first study assessing genetic variants contributing to HDL-C levels and coronary artery disease in the Mexican population. Our GWAS revealed for the first time that the *SIDT2*/Val636Ile variant is associated with increased HDL-C and phospholipid levels and decreased risk of CAD. We also provide evidence that the *SIDT2*/Val636Ile variant is functional, increasing the uptake of a cholesterol analog *in vitro*. Our data support a role of SIDT2 in cholesterol and lipid metabolism. The mechanisms by which this protein affects lipid and metabolic parameters in humans require further investigation.



593 The datasets supporting the current study have not been deposited in a public repository 594 because they are part of other studies in progress, but are available from the corresponding 595 authors on reasonable request.

### **REFERENCES**

- 598 1. Castelli, W.P. (1988). Cholesterol and lipids in the risk of coronary artery disease--the<br>599 **Framingham Heart Study. Can J Cardiol 4 Suppl A**, 5A-10A. Framingham Heart Study. Can J Cardiol 4 Suppl A, 5A-10A.
- 2. Boden, W.E. (2000). High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs
- High--Density Lipoprotein Intervention Trial. Am J Cardiol 86, 19L-22L. 603 3. Sharrett, A.R., Ballantyne, C.M., Coady, S.A., Heiss, G., Sorlie, P.D., Catellier, D., Patsch, W., 604 and Atherosclerosis Risk in Communities Study, G. (2001). Coronary heart disease and Atherosclerosis Risk in Communities Study, G. (2001). Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104, 1108-1113.
- 4. Barter, P.J., Puranik, R., and Rye, K.A. (2007). New insights into the role of HDL as an antiinflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 9, 493-610 498.<br>611 5. Mitchell, E
- 5. Mitchell, B.D., Kammerer, C.M., Blangero, J., Mahaney, M.C., Rainwater, D.L., Dyke, B., Hixson, J.E., Henkel, R.D., Sharp, R.M., Comuzzie, A.G., et al. (1996). Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The 614 San Antonio Family Heart Study. Circulation 94, 2159-2170.<br>615 6. Qasim, A., and Rader, D.J. (2006). Human genetics of variation in
- 6. Qasim, A., and Rader, D.J. (2006). Human genetics of variation in high-density lipoprotein cholesterol. Curr Atheroscler Rep 8, 198-205.
- 7. Gao, C., Tabb, K.L., Dimitrov, L.M., Taylor, K.D., Wang, N., Guo, X., Long, J., Rotter, J.I., Watanabe, R.M., Curran, J.E., et al. (2018). Exome Sequencing Identifies Genetic Variants Associated with Circulating Lipid Levels in Mexican Americans: The Insulin
- 620 Resistance Atherosclerosis Family Study (IRASFS). Sci Rep 8, 5603.<br>621 8. Williams, P.T. (2020). Quantile-specific heritability of high-density lipoprote 621 8. Williams, P.T. (2020). Quantile-specific heritability of high-density lipoproteins with 622 implications for precision medicine. J Clin Lipidol 14, 448-458 e440. 622 implications for precision medicine. J Clin Lipidol 14, 448-458 e440.<br>623 9. Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson, A.C., Stylianou,
- 9. Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson, A.C., Stylianou, I.M., Koseki, M., Pirruccello, J.P., Ripatti, S., Chasman, D.I., Willer, C.J., et al. (2010). Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707-713.
- 10. Willer, C.J., Schmidt, E.M., Sengupta, S., Peloso, G.M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., Buchkovich, M.L., Mora, S., et al. (2013). Discovery and refinement of loci associated with lipid levels. Nat Genet 45, 1274-1283.
- 629 11. Wu, Y., Waite, L.L., Jackson, A.U., Sheu, W.H., Buyske, S., Absher, D., Arnett, D.K., 630<br>630 Boerwinkle, E., Bonnycastle, L.L., Carty, C.L., et al. (2013). Trans-ethnic fine-map Boerwinkle, E., Bonnycastle, L.L., Carty, C.L., et al. (2013). Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet 9, e1003379.
- 12. Klarin, D., Damrauer, S.M., Cho, K., Sun, Y.V., Teslovich, T.M., Honerlaw, J., Gagnon, D.R., DuVall, S.L., Li, J., Peloso, G.M., et al. (2018). Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nat Genet 50, 1514-1523.
- 13. Weissglas-Volkov, D., Aguilar-Salinas, C.A., Nikkola, E., Deere, K.A., Cruz-Bautista, I., Arellano-Campos, O., Munoz-Hernandez, L.L., Gomez-Munguia, L., Ordonez-Sanchez, M.L., Reddy, P.M., et al. (2013). Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci. J Med Genet 50, 298-308.
- 14. Ko, A., Cantor, R.M., Weissglas-Volkov, D., Nikkola, E., Reddy, P.M., Sinsheimer, J.S., Pasaniuc, B., Brown, R., Alvarez, M., Rodriguez, A., et al. (2014). Amerindian-specific regions under positive selection harbour new lipid variants in Latinos. Nat Commun 5, 643 3983.<br>644 15. Below. J.I
- 15. Below, J.E., Parra, E.J., Gamazon, E.R., Torres, J., Krithika, S., Candille, S., Lu, Y., Manichakul, A., Peralta-Romero, J., Duan, Q., et al. (2016). Meta-analysis of lipid-traits in

 Hispanics identifies novel loci, population-specific effects, and tissue-specific enrichment of eQTLs. Sci Rep 6, 19429. 648 16. Graff, M., Emery, L.S., Justice, A.E., Parra, E., Below, J.E., Palmer, N.D., Gao, C., Duan, Q., 649<br>649 Valladares-Salgado, A., Cruz, M., et al. (2017). Genetic architecture of lipid traits in the Valladares-Salgado, A., Cruz, M., et al. (2017). Genetic architecture of lipid traits in the Hispanic community health study/study of Latinos. Lipids Health Dis 16, 200. 651 17. Villarreal-Molina, M.T., Aguilar-Salinas, C.A., Rodriguez-Cruz, M., Riano, D., Villalobos-<br>652 Comparan, M., Coral-Vazquez, R., Menjivar, M., Yescas-Gomez, P., Konigsoerg- Comparan, M., Coral-Vazquez, R., Menjivar, M., Yescas-Gomez, P., Konigsoerg- Fainstein, M., Romero-Hidalgo, S., et al. (2007). The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes 56, 1881-1887. 18. Acuna-Alonzo, V., Flores-Dorantes, T., Kruit, J.K., Villarreal-Molina, T., Arellano-Campos, O., Hunemeier, T., Moreno-Estrada, A., Ortiz-Lopez, M.G., Villamil-Ramirez, H., Leon- Mimila, P., et al. (2010). A functional ABCA1 gene variant is associated with low HDL- cholesterol levels and shows evidence of positive selection in Native Americans. Hum Mol Genet 19, 2877-2885. 19. Voight, B.F., Peloso, G.M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M.K., Hindy, G., Holm, H., Ding, E.L., Johnson, T., et al. (2012). Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572-580. 664 20. Holmes, M.V., Asselbergs, F.W., Palmer, T.M., Drenos, F., Lanktree, M.B., Nelson, C.P., 665 [1999]<br>665 **Dale, C.E., Padmanabhan, S., Finan, C., Swerdlow**, D.I., et al. (2015). Mendelian Dale, C.E., Padmanabhan, S., Finan, C., Swerdlow, D.I., et al. (2015). Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 36, 539-550. 21. Kawashiri, M.A., Tada, H., Nomura, A., and Yamagishi, M. (2018). Mendelian randomization: 668 Its impact on cardiovascular disease. J Cardiol 72, 307-313.<br>669 22. Khera, A.V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Bu 22. Khera, A.V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M.F., Jafri, K., French, B.C., Phillips, J.A., Mucksavage, M.L., Wilensky, R.L., et al. (2011). Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364, 127- 135. 673 23. Solovieff, N., Cotsapas, C., Lee, P.H., Purcell, S.M., and Smoller, J.W. (2013). Pleiotropy in 674 complex traits: challenges and strategies. Nat Rev Genet 14, 483-495. complex traits: challenges and strategies. Nat Rev Genet 14, 483-495. 24. Kosmas, C.E., Christodoulidis, G., Cheng, J.W., Vittorio, T.J., and Lerakis, S. (2014). High- density lipoprotein functionality in coronary artery disease. Am J Med Sci 347, 504-508. 677 25. Burgess, S., Foley, C.N., Allara, E., Staley, J.R., and Howson, J.M.M. (2020). A robust and<br>678 efficient method for Mendelian randomization with hundreds of genetic variants. Nat efficient method for Mendelian randomization with hundreds of genetic variants. Nat Commun 11, 376. 26. Aguilar-Salinas, C.A., Olaiz, G., Valles, V., Torres, J.M., Gomez Perez, F.J., Rull, J.A., Rojas, R., Franco, A., and Sepulveda, J. (2001). High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res 42, 1298-1307. 27. Aguilar-Salinas, C.A., Canizales-Quinteros, S., Rojas-Martinez, R., Mehta, R., Villarreal- Molina, M.T., Arellano-Campos, O., Riba, L., Gomez-Perez, F.J., and Tusie-Luna, M.T. (2009). Hypoalphalipoproteinemia in populations of Native American ancestry: an opportunity to assess the interaction of genes and the environment. Curr Opin Lipidol 20, 688 92-97.<br>689 28. Hernandez 28. Hernandez-Alcaraz, C., Aguilar-Salinas, C.A., Mendoza-Herrera, K., Pedroza-Tobias, A., Villalpando, S., Shamah-Levy, T., Rivera-Dommarco, J., Hernandez-Avila, M., and Barquera, S. (2020). Dyslipidemia prevalence, awareness, treatment and control in Mexico: results of the Ensanut 2012. Salud Publica Mex 62, 137-146. 29. Villarreal-Molina, T., Posadas-Romero, C., Romero-Hidalgo, S., Antunez-Arguelles, E., Bautista-Grande, A., Vargas-Alarcon, G., Kimura-Hayama, E., Canizales-Quinteros, S., Juarez-Rojas, J.G., Posadas-Sanchez, R., et al. (2012). The ABCA1 gene R230C variant

696 is associated with decreased risk of premature coronary artery disease: the genetics of 697 atherosclerotic disease (GEA) study. PLoS One 7, e49285. 697 atherosclerotic disease (GEA) study. PLoS One 7, e49285. 698 30. Mendez-Acevedo, K.M., Valdes, V.J., Asanov, A., and Vaca, L. (2017). A novel family of 699 mammalian transmembrane proteins involved in cholesterol transport. Sci Rep 7, 7450. 700 31. Leon-Mimila, P., Villamil-Ramirez, H., Villalobos-Comparan, M., Villarreal-Molina, T., 701 Romero-Hidalgo, S., Lopez-Contreras, B., Gutierrez-Vidal, R., Vega-Badillo, J., Jacobo-702 Albavera, L., Posadas-Romeros, C., et al. (2013). Contribution of common genetic 703 variants to obesity and obesity-related traits in mexican children and adults. PLoS One 8, 704 e70640. 705 32. Macias-Kauffer, L.R., Villamil-Ramirez, H., Leon-Mimila, P., Jacobo-Albavera, L., Posadas-<br>706 Romero, C., Posadas-Sanchez, R., Lopez-Contreras, B.E., Moran-Ramos, S., Romero-706 Romero, C., Posadas-Sanchez, R., Lopez-Contreras, B.E., Moran-Ramos, S., Romero-<br>707 Hidalgo, S., Acuna-Alonzo, V., et al. (2019). Genetic contributors to serum uri 707 Hidalgo, S., Acuna-Alonzo, V., et al. (2019). Genetic contributors to serum uric acid 708 levels in Mexicans and their effect on premature coronary artery disease. Int J Cardiol 709 279, 168-173.<br>710 33. (2000). Obesity: p 33. (2000). Obesity: preventing and managing the global epidemic. Report of a WHO 711 consultation. World Health Organ Tech Rep Ser 894, i-xii, 1-253. 712 34. Kuczmarski, R.J., Ogden, C.L., Grummer-Strawn, L.M., Flegal, K.M., Guo, S.S., Wei, R., 713<br>713 Mei, Z., Curtin, L.R., Roche, A.F., and Johnson, C.L. (2000). CDC growth charts: Unit 713 Mei, Z., Curtin, L.R., Roche, A.F., and Johnson, C.L. (2000). CDC growth charts: United 714 States. Adv Data, 1-27. 715 35. Leon-Mimila, P., Vega-Badillo, J., Gutierrez-Vidal, R., Villamil-Ramirez, H., Villareal-Molina, 716 T., Larrieta-Carrasco, E., Lopez-Contreras, B.E., Kauffer, L.R., Maldonado-Pintado, D.G., 717 Mendez-Sanchez, N., et al. (2015). A genetic risk score is associated with hepatic Mendez-Sanchez, N., et al. (2015). A genetic risk score is associated with hepatic 718 triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity.<br>719 Exp Mol Pathol 98, 178-183. 719 Exp Mol Pathol 98, 178-183. 720 36. Friedewald, W.T., Levy, R.I., and Fredrickson, D.S. (1972). Estimation of the concentration<br>721 of low-density lipoprotein cholesterol in plasma, without use of the preparative 721 of low-density lipoprotein cholesterol in plasma, without use of the preparative<br>722 ultracentrifuge. Clin Chem 18, 499-502. 722 ultracentrifuge. Clin Chem 18, 499-502.<br>723 37. DeLong, D.M., DeLong, E.R., Wood, P.D., I 723 37. DeLong, D.M., DeLong, E.R., Wood, P.D., Lippel, K., and Rifkind, B.M. (1986). A<br>724 comparison of methods for the estimation of plasma low- and very low-density comparison of methods for the estimation of plasma low- and very low-density lipoprotein 725 cholesterol. The Lipid Research Clinics Prevalence Study. JAMA 256, 2372-2377. 726 38. National Cholesterol Education Program Expert Panel on Detection, E., and Treatment of 727<br>727 High Blood Cholesterol in, A. (2002). Third Report of the National Cholesterol Educatic 727 High Blood Cholesterol in, A. (2002). Third Report of the National Cholesterol Education<br>728 Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 728 Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood<br>729 Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-342 729 Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421. 730 39. Parker, B.L., Calkin, A.C., Seldin, M.M., Keating, M.F., Tarling, E.J., Yang, P., Moody, S.C., 731 Liu, Y., Zerenturk, E.J., Needham, E.J., et al. (2019). An integrative systems genetic 731 Liu, Y., Zerenturk, E.J., Needham, E.J., et al. (2019). An integrative systems genetic analysis of mammalian lipid metabolism. Nature 567, 187-193. 733 40. Huynh, K., Barlow, C.K., Jayawardana, K.S., Weir, J.M., Mellett, N.A., Cinel, M., Magliano, 734 D.J., Shaw, J.E., Drew, B.G., and Meikle, P.J. (2019). High-Throughput Plasma 735 Lipidomics: Detailed Mapping of the Associations with Cardiometabolic Risk Factors. Cell 736 Chem Biol 26, 71-84 e74. 737 41. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., 738 Sklar, P., de Bakker, P.I., Daly, M.J., et al. (2007). PLINK: a tool set for whole-genome<br>739 sesociation and population-based linkage analyses. Am J Hum Genet 81, 559-575. 739 association and population-based linkage analyses. Am J Hum Genet 81, 559-575. 740 42. Browning, B.L., and Browning, S.R. (2016). Genotype Imputation with Millions of Reference 741 Samples. Am J Hum Genet 98, 116-126. 742 43. Corbin, L.J., Richmond, R.C., Wade, K.H., Burgess, S., Bowden, J., Smith, G.D., and 743 Timpson, N.J. (2016). BMI as a Modifiable Risk Factor for Type 2 Diabetes: Refining and 744 Understanding Causal Estimates Using Mendelian Randomization. Diabetes 65, 3002- 3007.

- 746 44. Burgess, S., Butterworth, A., and Thompson, S.G. (2013). Mendelian randomization analysis<br>747 with multiple genetic variants using summarized data. Genet Epidemiol 37, 658-665. with multiple genetic variants using summarized data. Genet Epidemiol 37, 658-665.<br>748 – 45. Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with inv
- 748 45. Bowden, J., Davey Smith, G., and Burgess, S. (2015). Mendelian randomization with invalid<br>749 http://ect.estimation and bias detection through Egger regression. Int J 749 instruments: effect estimation and bias detection through Egger regression. Int J<br>750 **Epidemiol 44, 512-525**.
- 750 Epidemiol 44, 512-525. 751 46. Yavorska, O.O., and Burgess, S. (2017). MendelianRandomization: an R package for 752 performing Mendelian randomization analyses using summarized data. Int J Epidemiol 753 46, 1734-1739.
- 754 47. Alexander, D.H., Novembre, J., and Lange, K. (2009). Fast model-based estimation of 755<br>755 ancestry in unrelated individuals. Genome Res 19, 1655-1664. ancestry in unrelated individuals. Genome Res 19, 1655-1664.
- 756 48. Maples, B.K., Gravel, S., Kenny, E.E., and Bustamante, C.D. (2013). RFMix: a discriminative 757 modeling approach for rapid and robust local-ancestry inference. Am J Hum Genet 93,
- 758 278-288. 759 49. Sabeti, P.C., Reich, D.E., Higgins, J.M., Levine, H.Z., Richter, D.J., Schaffner, S.F., Gabriel, 760<br>760 S.B., Platko, J.V., Patterson, N.J., McDonald, G.J., et al. (2002). Detecting recent S.B., Platko, J.V., Patterson, N.J., McDonald, G.J., et al. (2002). Detecting recent 761 positive selection in the human genome from haplotype structure. Nature 419, 832-837.
- 762 50. Szpiech, Z.A., and Hernandez, R.D. (2014). selscan: an efficient multithreaded program to 763 perform EHH-based scans for positive selection. Mol Biol Evol 31, 2824-2827.
- 764 51. Bennett, B.J., Davis, R.C., Civelek, M., Orozco, L., Wu, J., Qi, H., Pan, C., Packard, R.R., 765<br>765 Eskin, E., Yan, M., et al. (2015). Genetic Architecture of Atherosclerosis in Mice: A 765 Eskin, E., Yan, M., et al. (2015). Genetic Architecture of Atherosclerosis in Mice: A
- 766 Systems Genetics Analysis of Common Inbred Strains. PLoS Genet 11, e1005711. 52. Puppione, D.L., and Charugundla, S. (1994). A microprecipitation technique suitable for 768 measuring alpha-lipoprotein cholesterol. Lipids 29, 595-597.
- 769 53. Hedrick, C.C., Castellani, L.W., Warden, C.H., Puppione, D.L., and Lusis, A.J. (1993). 770 Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol
- 771 Chem 268, 20676-20682. 54. Ghazalpour, A., Bennett, B., Petyuk, V.A., Orozco, L., Hagopian, R., Mungrue, I.N., Farber, 773 C.R., Sinsheimer, J., Kang, H.M., Furlotte, N., et al. (2011). Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet 7, e1001393.
- 775 55. Bennett, B.J., Farber, C.R., Orozco, L., Kang, H.M., Ghazalpour, A., Siemers, N., Neubauer, 776 M., Neuhaus, I., Yordanova, R., Guan, B., et al. (2010). A high-resolution association mapping panel for the dissection of complex traits in mice. Genome Res 20, 281-290.<br>778 56. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., and Storey, J.D. (2012). The sva
- 778 56. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., and Storey, J.D. (2012). The sva<br>779 package for removing batch effects and other unwanted variation in high-throughp 779 package for removing batch effects and other unwanted variation in high-throughput<br>780 experiments. Bioinformatics 28. 882-883.
- 780 experiments. Bioinformatics 28, 882-883. 781 57. Hui, S.T., Kurt, Z., Tuominen, I., Norheim, F., R, C.D., Pan, C., Dirks, D.L., Magyar, C.E.,<br>782 French. S.W., Chella Krishnan, K., et al. (2018). The Genetic Architecture of Diet-French, S.W., Chella Krishnan, K., et al. (2018). The Genetic Architecture of Diet-783 Induced Hepatic Fibrosis in Mice. Hepatology 68, 2182-2196.
- 784 58. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S.L. (2013). 785 TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions
- 786 and gene fusions. Genome Biol 14, R36.<br>787 59. Trapnell, C., Williams, B.A., Pertea, G., Morta 787 59. Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., Salzberg, S.L., Wold, B.J., and Pachter, L. (2010). Transcript assembly and quantification by RNA-789 Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat 790 Biotechnol 28, 511-515.
- 791 60. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of 792 genomewide association scans. Bioinformatics 26, 2190-2191.
- 793 61. Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011). GCTA: a tool for genome-794 wide complex trait analysis. Am J Hum Genet 88, 76-82.

- 795 62. Rucker, G., Schwarzer, G., Carpenter, J.R., Binder, H., and Schumacher, M. (2011).<br>796 Treatment-effect estimates adiusted for small-study effects via a limit meta-analy 796 Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis. 797 Biostatistics 12, 122-142.
- 798 63. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke, 799 M., Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization of 799 M., Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization of
- 800 genome-wide association scan results. Bioinformatics 26, 2336-2337. 801 64. Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted correlation<br>802 enetwork analysis. BMC Bioinformatics 9, 559. 802 network analysis. BMC Bioinformatics 9, 559.<br>803 65. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodak
- 803 65. Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A.H., Tanaseichuk, O., Benner, C., 804 and Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the and Chanda, S.K. (2019). Metascape provides a biologist-oriented resource for the
- 805 analysis of systems-level datasets. Nat Commun 10, 1523. 806 66. Chen, J., Bardes, E.E., Aronow, B.J., and Jegga, A.G. (2009). ToppGene Suite for gene list 807 enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37, W305-311.<br>808 67. Reimand, J., Isserlin, R., Voisin, V., Kucera, M., Tannus-Lopes, C., Rostamianfar, A., Wadi,
- 808 67. Reimand, J., Isserlin, R., Voisin, V., Kucera, M., Tannus-Lopes, C., Rostamianfar, A., Wadi, 809 L., Meyer, M., Wong, J., Xu, C., et al. (2019). Pathway enrichment analysis and L., Meyer, M., Wong, J., Xu, C., et al. (2019). Pathway enrichment analysis and 810 visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc 14, 482-517.
- 812 68. Kontush, A., Lhomme, M., and Chapman, M.J. (2013). Unraveling the complexities of the 813 813 HDL lipidome. J Lipid Res 54, 2950-2963.<br>814 69. Ding. M., and Rexrode. K.M. (2020). A Review
- 814 69. Ding, M., and Rexrode, K.M. (2020). A Review of Lipidomics of Cardiovascular Disease<br>815 Highlights the Importance of Isolating Lipoproteins. Metabolites 10. 815 Highlights the Importance of Isolating Lipoproteins. Metabolites 10.<br>816 70. Rojas, R., Aguilar-Salinas, C.A., Jimenez-Corona, A., Shamah-Levy, T
- 816 70. Rojas, R., Aguilar-Salinas, C.A., Jimenez-Corona, A., Shamah-Levy, T., Rauda, J., Avila-817 Burgos, L., Villalpando, S., and Ponce, E.L. (2010). Metabolic syndrome in Mexican<br>818 adults: results from the National Health and Nutrition Survey 2006. Salud Publica Me 818 adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex 52<br>819 Suppl 1, S11-18.
- 819 Suppl 1, S11-18.<br>820 71. Oliveira, H.C.F., and 820 71. Oliveira, H.C.F., and Raposo, H.F. (2020). Cholesteryl Ester Transfer Protein and Lipid<br>821 Metabolism and Cardiovascular Diseases. Adv Exp Med Biol 1276, 15-25. 821 Metabolism and Cardiovascular Diseases. Adv Exp Med Biol 1276, 15-25.<br>822 72. Ponce, X., Rodriguez-Ramirez, S., Mundo-Rosas, V., Shamah, T., Barguera, S
- 822 72. Ponce, X., Rodriguez-Ramirez, S., Mundo-Rosas, V., Shamah, T., Barquera, S., and<br>823 **Conzalez de Cossio, T. (2014). Dietary quality indices vary with sociodemographic** Gonzalez de Cossio, T. (2014). Dietary quality indices vary with sociodemographic 824 variables and anthropometric status among Mexican adults: a cross-sectional study. 825 Results from the 2006 National Health and Nutrition Survey. Public Health Nutr 17, 1717-<br>826 1728. 826 1728.<br>827 73. Gomboja
- 827 73. Gombojav, B., Lee, S.J., Kho, M., Song, Y.M., Lee, K., and Sung, J. (2016). Multiple 828 susceptibility loci at chromosome 11q23.3 are associated with plasma triglyceride 828 susceptibility loci at chromosome 11q23.3 are associated with plasma triglyceride in East<br>829 Asians. J Lipid Res 57, 318-324.
- 829 Asians. J Lipid Res 57, 318-324.<br>830 74. Moon, S., Lee, Y., Won, S., and Lee, 830 74. Moon, S., Lee, Y., Won, S., and Lee, J. (2018). Multiple genotype-phenotype association<br>831 study reveals intronic variant pair on SIDT2 associated with metabolic syndrome in a study reveals intronic variant pair on SIDT2 associated with metabolic syndrome in a 832 Korean population. Hum Genomics 12, 48.
- 833 75. Prats-Uribe, A., Sayols-Baixeras, S., Fernandez-Sanles, A., Subirana, I., Carreras-Torres, 834 R., Vilahur, G., Civeira, F., Marrugat, J., Fito, M., Hernaez, A., et al. (2020). High-density<br>835 lipoprotein characteristics and coronary artery disease: a Mendelian randomization study 835 lipoprotein characteristics and coronary artery disease: a Mendelian randomization study.<br>836 Metabolism 112, 154351. 836 Metabolism 112, 154351.<br>837 76. Karjalainen, M.K., Holmes, M
- 76. Karjalainen, M.K., Holmes, M.V., Wang, Q., Anufrieva, O., Kahonen, M., Lehtimaki, T., 838 Havulinna, A.S., Kristiansson, K., Salomaa, V., Perola, M., et al. (2020). Apolipoprotein 839 A-I concentrations and risk of coronary artery disease: A Mendelian randomization study.
- 840 Atherosclerosis 299, 56-63.<br>841 77. Richardson, T.G., Sanderson, E 77. Richardson, T.G., Sanderson, E., Palmer, T.M., Ala-Korpela, M., Ference, B.A., Davey 842 Smith, G., and Holmes, M.V. (2020). Evaluating the relationship between circulating 843 lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable<br>844 Mendelian randomisation analysis. PLoS Med 17, e1003062. Mendelian randomisation analysis. PLoS Med 17, e1003062.

- 845 78. Ference, B.A., Kastelein, J.J.P., Ray, K.K., Ginsberg, H.N., Chapman, M.J., Packard, C.J., 846<br>846 Laufs. U., Oliver-Williams. C., Wood. A.M., Butterworth. A.S., et al. (2019). Association 846 Laufs, U., Oliver-Williams, C., Wood, A.M., Butterworth, A.S., et al. (2019). Association of 847 Clauforceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of 847 Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of 848 Coronary Heart Disease. JAMA 321, 364-373. 848 Coronary Heart Disease. JAMA 321, 364-373.<br>849 79. Zuber, V., Gill, D., Ala-Korpela, M., Langenberg, C
- 849 79. Zuber, V., Gill, D., Ala-Korpela, M., Langenberg, C., Butterworth, A., Bottolo, L., and<br>850 Burgess, S. (2020). High-throughput multivariable Mendelian randomization analy 850 Burgess, S. (2020). High-throughput multivariable Mendelian randomization analysis 851 prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease. medRxiv, 852 852 2020.2002.2010.20021691.<br>853 80. Marmillot, P., Patel, S., and Lak
- 853 80. Marmillot, P., Patel, S., and Lakshman, M.R. (2007). Reverse cholesterol transport is 854 requilated by varying fatty acyl chain saturation and sphingomyelin content in regulated by varying fatty acyl chain saturation and sphingomyelin content in
- 855 reconstituted high-density lipoproteins. Metabolism 56, 251-259.<br>856 81. Zerrad-Saadi, A., Therond, P., Chantepie, S., Couturier, M., Rye, K. 856 81. Zerrad-Saadi, A., Therond, P., Chantepie, S., Couturier, M., Rye, K.A., Chapman, M.J., and<br>857 Kontush, A. (2009). HDL3-mediated inactivation of LDL-associated phospholipid 857 Kontush, A. (2009). HDL3-mediated inactivation of LDL-associated phospholipid<br>858 hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL 858 hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle<br>859 surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb 860 Vasc Biol 29, 2169-2175.
- 861 82. Hancock-Cerutti, W., Lhomme, M., Dauteuille, C., Lecocq, S., Chapman, M.J., Rader, D.J., 862 Kontush, A., and Cuchel, M. (2017). Paradoxical coronary artery disease in humans with<br>863 hyperalphalipoproteinemia is associated with distinct differences in the high-density 863 hyperalphalipoproteinemia is associated with distinct differences in the high-density<br>864 lipoprotein phosphosphingolipidome. J Clin Lipidol 11. 1192-1200 e1193. lipoprotein phosphosphingolipidome. J Clin Lipidol 11, 1192-1200 e1193.
- 865 83. Camont, L., Lhomme, M., Rached, F., Le Goff, W., Negre-Salvayre, A., Salvayre, R., 866 (Calzada, C., Lagarde, M., Chapman, M.J., and Kontush, A. (2013). Small, dense Calzada, C., Lagarde, M., Chapman, M.J., and Kontush, A. (2013). Small, dense high-867 density lipoprotein-3 particles are enriched in negatively charged phospholipids:<br>868 relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflamn relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory,
- 869 and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 33, 2715-2723. 870 84. Holzer, M., Birner-Gruenberger, R., Stojakovic, T., El-Gamal, D., Binder, V., Wadsack, C., 871 [1994]<br>871 Heinemann, A., and Marsche, G. (2011). Uremia alters HDL composition and function. 871 Heinemann, A., and Marsche, G. (2011). Uremia alters HDL composition and function. J<br>872 Am Soc Nephrol 22, 1631-1641. 872 Am Soc Nephrol 22, 1631-1641.<br>873 85. Darabi, M., and Kontush, A. (2016).
- 85. Darabi, M., and Kontush, A. (2016). Phosphatidylserine in atherosclerosis. Curr Opin Lipidol 874 27, 414-420.
- 875 86. Jialin, G., Xuefan, G., and Huiwen, Z. (2010). SID1 transmembrane family, member 2 876 (Sidt2): a novel lysosomal membrane protein. Biochem Biophys Res Commun 402, 588- 877<br>878
- 878 87. Ren, R., Xu, X., Lin, T., Weng, S., Liang, H., Huang, M., Dong, C., Luo, Y., and He, J.<br>879 (2011). Cloning, characterization, and biological function analysis of the SidT2 gen 879 (2011). Cloning, characterization, and biological function analysis of the SidT2 gene from<br>880 Siniperca chuatsi. Dev Comp Immunol 35, 692-701. Siniperca chuatsi. Dev Comp Immunol 35, 692-701.
- 881 88. Li, W., Koutmou, K.S., Leahy, D.J., and Li, M. (2015). Systemic RNA Interference 882 Deficiency-1 (SID-1) Extracellular Domain Selectively Binds Long Double-stranded RNA 883 and Is Required for RNA Transport by SID-1. J Biol Chem 290, 18904-18913.
- 884 89. Aizawa, S., Contu, V.R., Fujiwara, Y., Hase, K., Kikuchi, H., Kabuta, C., Wada, K., and 885 Kabuta, T. (2017). Lysosomal membrane protein SIDT2 mediates the direct uptake of 886 886 **DNA by lysosomes. Autophagy 13, 218-222.**<br>887 90. Nguyen, T.A., Smith, B.R.C., Elgass, K.D., Cree
- 887 90. Nguyen, T.A., Smith, B.R.C., Elgass, K.D., Creed, S.J., Cheung, S., Tate, M.D., Belz, G.T., 888 Wicks, I.P., Masters, S.L., and Pang, K.C. (2019). SIDT1 Localizes to Endolysosomes 889 and Mediates Double-Stranded RNA Transport into the Cytoplasm. J Immunol 202, 890 3483-3492.
- 891 91. Hase, K., Contu, V.R., Kabuta, C., Sakai, R., Takahashi, M., Kataoka, N., Hakuno, F., 892 Takahashi, S.I., Fujiwara, Y., Wada, K., et al. (2020). Cytosolic domain of SIDT2 carries 893 an arginine-rich motif that binds to RNA/DNA and is important for the direct transport of 894 nucleic acids into lysosomes. Autophagy, 1-15. nucleic acids into lysosomes. Autophagy, 1-15.

- 895 92. Valdes, V.J., Athie, A., Salinas, L.S., Navarro, R.E., and Vaca, L. (2012). CUP-1 is a novel<br>896 brotein involved in dietary cholesterol uptake in Caenorhabditis elegans. PLoS One 7. 896 protein involved in dietary cholesterol uptake in Caenorhabditis elegans. PLoS One 7, 897 e33962.<br>898 93. Hulce, J.J.,
- 898 93. Hulce, J.J., Cognetta, A.B., Niphakis, M.J., Tully, S.E., and Cravatt, B.F. (2013). Proteome-<br>899 wide mapping of cholesterol-interacting proteins in mammalian cells. Nat Methods 10, 899 wide mapping of cholesterol-interacting proteins in mammalian cells. Nat Methods 10,
- 900 259-264.<br>901 94. Sharpe, L.J., 901 94. Sharpe, L.J., Rao, G., Jones, P.M., Glancey, E., Aleidi, S.M., George, A.M., Brown, A.J., and<br>902 Gelissen. I.C. (2015). Cholesterol sensing by the ABCG1 lipid transporter: Requirement 902 Gelissen, I.C. (2015). Cholesterol sensing by the ABCG1 lipid transporter: Requirement 903 of a CRAC motif in the final transmembrane domain. Biochim Biophys Acta 1851, 956- 964.
- 905 95. Ouimet, M., Franklin, V., Mak, E., Liao, X., Tabas, I., and Marcel, Y.L. (2011). Autophagy 906 regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell
- 907 Metab 13, 655-667.<br>908 96. Chen, X., Gu, X., and Z 908 96. Chen, X., Gu, X., and Zhang, H. (2018). Sidt2 regulates hepatocellular lipid metabolism<br>909 through autophagy. J Lipid Res 59, 404-415. through autophagy. J Lipid Res 59, 404-415.
- 910 97. Gao, J., Gu, X., Mahuran, D.J., Wang, Z., and Zhang, H. (2013). Impaired glucose tolerance<br>911 **https://www.inamousemodel of sidt2 deficiency**. PLoS One 8, e66139. 911 in a mouse model of sidt2 deficiency. PLoS One 8, e66139.<br>912 98. Chang, G., Yang, R., Cao, Y., Nie, A., Gu, X., and Zhang, H. (20
- 912 98. Chang, G., Yang, R., Cao, Y., Nie, A., Gu, X., and Zhang, H. (2016). SIDT2 is involved in the 913 values NAADP-mediated release of calcium from insulin secretory granules. J Mol Endocrinol 913 NAADP-mediated release of calcium from insulin secretory granules. J Mol Endocrinol 914 56, 249-259.<br>915 99. Gao, J., Zhang, Y
- 915 99. Gao, J., Zhang, Y., Yu, C., Tan, F., and Wang, L. (2016). Spontaneous nonalcoholic fatty liver disease and ER stress in Sidt2 deficiency mice. Biochem Biophys Res Commun 917 476, 326-332.<br>
918 100. Meng, Y., Wang
- 918 100. Meng, Y., Wang, L., and Ling, L. (2018). Changes of lysosomal membrane permeabilization 919 and lipid metabolism in sidt2 deficient mice. Exp Ther Med 16, 246-252.
- 920
- 921
- 922

#### **FIGURE TITLES AND LEGENDS**

 **Figure 1. Manhattan plot for HDL-C levels in the discovery phase.** Plot showing the -log10 transformed *P*-value of SNPs for 2153 Mexican children and adults. The red line indicates the 927 genome-wide significance level ( $P=5x10^{-8}$ ). Genes closest to the SNP with the lowest P-value at each locus are indicated.

 **Figure 2. Locus zoom view of variants within the 11q23 region (***SIDT2* **locus) associated with HDL-C levels.** SNPs are colored based on their correlation (r<sup>2</sup>) with the *SIDT2/Val636Ile* variant (purple diamond), which showed the strongest association with HDL-C levels (*P*=1.5x10-  $\frac{11}{1}$ . Arrows on the horizontal blue lines show the direction of transcription, and rectangles represent exons. *P-*values indicate significance of associations found in the discovery phase.

 **Figure 3. Heat map of associations between the** *SIDT2***/Val636Ile variant and lipid classes in the MOBES cohort.** Color intensity reflects the Beta value (red for positive, blue for negative) obtained from linear regression between *SIDT2*/Val636Ile and lipid classes in the MOBES study (n=375) adjusted by age, sex and BMI. \**P*-value ≤0.05, \*\* *P*-value ≤0.001.

 **Figure 4. Uptake of the blue fluorescent cholesterol analog dehydroergosterol (DHE) by cells expressing wildtype and Ile636/SIDT2.** (A) Confocal microscopy images of HEK293T cells expressing the empty vector, wildtype and Ile636/SIDT2, at times 2.5, 3.5 and 5 minutes after adding the fluorescent cholesterol analog DHE to the culture. (B) Plot showing mean 945 fluorescence intensity over time after adding DHE to the culture. Values show mean ± standard deviations from at least 4 independent experiments, each experiment shows mean values from all the cells in the focal plane. The red dots represent cells transfected with the empty vector; the black dots represent cells expressing wildtype SIDT2, and blue dots represent cells expressing Ile636/SIDT2. Addition of DHE is indicated with an arrow. \**P*<0.05; \*\**P*<0.01.

 **Figure 5. Liver** *SIDT2* **expression and lipids in mice and humans.** Correlations of liver *Sidt2*  expression with HDL-C, total cholesterol, and TG serum levels in MOBES cohort participants (A) and mice from the HMDP (B)**.** (C) Venn diagram depicting the overlap of genes significantly correlated with *SIDT2* liver expression in HMDP mice and MOBES cohort participants 955 ( $P$ <1.0x10<sup>-8</sup>). (D) Significantly enriched pathways in mice and humans.

 **Video S1. Uptake of the fluorescent cholesterol analog dehydroergosterol (DHE) in HEK293T cells expressing wildtype or Ile636/SIDT2.** Representative experiments illustrating cells in the focal plane. Fluorescence was monitored in time using confocal microscopy. DHE uptake in cells expressing the empty vector (upper panel), wildtype SIDT2 and the Ile636/SIDT2 proteins (lower panels).

<b>CHR: position</b> (hg19)	Locus	rs ID	Type of variant	$\beta$ HDL-C (SE)	P-value
6: 160921566	LPAL <sub>2</sub>	rs9457930	Intron variant	1.19(0.33)	$6.93 \times 10^{-6}$
8: 9177732	PRPF31, PPP1R3B, TNKS	rs983309	Intron variant	$-1.83(0.34)$	$4.48 \times 10^{-6}$
9: 107589134	ABCA1	rs4149310	Intron variant	1.44(0.32)	$7.25 \times 10^{-7}$
9:107620835	ABCA1	rs9282541	Missense variant	$-3.44(0.48)$	$3.99 \times 10^{-13}$
11: 116633947	BUD13-ZPR1-APOC3- APOA4-APOA5-APOA1	rs10488698	Missense variant	2.38(0.44)	$8.17 \times 10^{-8}$
11: 117063003	SIDT <sub>2</sub>	rs17120425	Missense variant	3.31(0.51)	$1.52 \times 10^{-11}$
12:43679673	ADAMTS20	rs1514661	Regulatory region variant	1.12(0.34)	$4.23 \times 10^{-6}$
15: 58723479	LIPC, ALDH1A2	rs1077834	Intron variant	$-1.55(0.33)$	$8.57 \times 10^{-7}$
16: 56985555	<b>CETP</b>	rs12448528	Regulatory region variant	$-2.79(0.39)$	5.92 x 10-15
16: 56999328	<b>CETP</b>	rs11508026	Intron variant	3.02(0.32)	4.46 x 10-18

**Table 1. Lead SNPs associated with HDL-C levels in the meta-analysis including Mexican children and adults.**

HDL-C values were log transformed for the analysis. Effect sizes were calculated for minor alleles. *P*-values for additive models were adjusted for sex, age, and either BMI or BMI percentile in children (n=2,153). HDL-C, High-density lipoprotein cholesterol; CHR: Chromosome; SE, Standard error.



**Table 2. Association of selected SNPs with lipid traits in the GEA cohort.**

LDL-C, TG, ApoA1 and ApoB levels were log transformed for the analysis. Effect sizes were calculated for the minor alleles. P-values for additive models were adjusted for sex, age, and BMI (n=1,559). CHR: Chromosome; MAF, minor allele frequency; HDL-C, High density lipoprotein cholesterol; TC, Total cholesterol; LDL-C, Low density lipoprotein cholesterol; TG, Triglycerides; ApoA1, Apolipoprotein A1; ApoB, Apolipoprotein B.



### **Table 3. Association of selected SNPs with lipid traits in the MOBES cohort.**

LDL-C and TG levels were log transformed for the analysis. Effect size was calculated for the minor alleles. P-values for additive models were adjusted for sex, age, and BMI (n=555). CHR: Chromosome; MAF, minor allele frequency; HDL-C, High-density lipoprotein cholesterol; TC, Total cholesterol; LDL-C, Low-density lipoprotein cholesterol; TG, Triglycerides.



**Table 4. Association of HDL-C associated SNPs with premature coronary artery disease in the GEA cohort.**

Associations with premature CAD were adjusted for age, sex and BMI. *P*-values were calculated by logistic regression. HDL-C, High-density lipoprotein cholesterol; CHR: Chromosome; MAF, minor allele frequency; CAD, coronary artery disease; OR, Odds ratio; CI, confidence interval.

# **Figure 1**



Plotted SNPs WINNING  $\mathbb{R}$  and  $\mathbb{R}$  are the contract of the contract of the contract of  $\mathbb{R}$  . The contract of  $\mathbb{R}$  $|||$  $\| \cdot \| \cdot \|$ 



## **Figure 3**





# **Figure 4**

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2020.09.19.20197673;](https://doi.org/10.1101/2020.09.19.20197673) this version posted September 20, 2020. The copyright holder for this



\*

**Figure 5**

